ClinicalTrials.gg
CompletedNCT02988115CLEAR SerenityUpdated Apr 3, 2020Results posted

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

A Phase 3 interventional study of bempedoic acid and placebo in Hypercholesterolemia, Atherosclerotic Cardiovascular Disease and Statin Adverse Reaction, sponsored by Esperion Therapeutics, Inc.. Completed at 67 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Esperion Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
6th of 21
345 · median 126
Started
2016
with 3 others
Phase 3
7 of 21
1 open now
Registered
8th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 6th largest by enrollment, is one of 4 that started in 2016, is one of 7 in phase 3, and was the 8th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.

03

Conditions studied

  • Hypercholesterolemia
  • Atherosclerotic Cardiovascular Disease
  • Statin Adverse Reaction

Keywords

  • hyperlipidemia
  • cholesterol
  • familial hypercholesterolemia
  • atherosclerotic cardiovascular disease
  • ASCVD
  • HeFH
  • LDL
  • statin intolerance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Require lipid-modifying therapy for primary or secondary prevention of cardiovascular disease
  • Fasting LDL-C ≥130 mg/dL for primary prevention or LDL-C ≥100 mg/dL for secondary prevention (history of HeFH and/or ASCVD)
  • Be statin-intolerant (unable to tolerate 2 or more statins)

Exclusion criteria

Exclusion Criteria:

  • Total fasting triglyceride ≥500 mg/dL
  • Renal dysfunction or nephrotic syndrome or history of nephritis
  • (BMI) ≥50 kg/m2
  • Significant cardiovascular disease or cardiovascular event in the past 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    bempedoic acid

    bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

    Drug: bempedoic acid

  • Placebo comparator
    placebo

    Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

    Other: placebo

Interventions

  • bempedoic acid 180 mg tablet

    Also known as: ETC-1002

  • Otherplacebo

    Matching placebo tablet

    Also known as: placebo control

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12

    PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at Week 24

    PCFB was calculated as the (\[post-BL value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available then that single value was used as BL. PCFB in LDL-C was analyzed using ANCOVA, with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

    Time frame: Baseline; Week 24

  2. Percent Change From Baseline in the Lipid Profile at Week 12

    PCFB was calculated as: (\[post-BL value minus the BL value\] divided by the BL value) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. apoB and TC BL were defined as the last non-missing value on/prior to Day 1. PCFB was analyzed using ANCOVA, with treatment and group stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing data at Week 12 who were no longer taking study treatment (ST), missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking ST, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

    Time frame: Baseline; Week 12

  3. Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12

    Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline for hsCRP is defined as the last non-missing value on or prior to Day 1. Percent change from Baseline in hsCRP, non-parametric (Wilcoxon rank-sum test) analysis with Hodges-Lehmann estimates and confidence interval was performed.

    Time frame: Baseline; Week 12

  4. Absolute Change From Baseline in LDL-C at Week 12 and Week 24

    Change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the last two non-missing values on or prior to Day 1.

    Time frame: Baseline; Week 12; Week 24

07

Results

Posted Apr 3, 2020

Participant flow

602 participants were screened; out of 602, 345 participants were randomized. 76 participants discontinued investigational medicinal product (IMP), and 18 participants withdrew from the study.

Participant flow — Overall Study
MilestoneBempedoic AcidPlacebo
Started234111
Completed220107
Not completed144
Withdrew: Adverse event61
Withdrew: Sponsor decision52
Withdrew: Withdrawal by subject11
Withdrew: Withdrawn by mistake10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12

PCFB was calculated as the (\[post-Baseline (BL) value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changeBempedoic AcidPlacebo
Percent Change From Baseline (PCFB) in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12-22.58 ± 1.290-1.17 ± 1.421
Statistical analysis
  • Bempedoic Acid vs Placebo · ANCOVA · p = <0.001 · Least squares means difference: -21.41 · 95% CI -25.132 to -17.697bempedoic acid (BA) therapy minus placebo
SecondaryPercent Change From Baseline in LDL-C at Week 24

PCFB was calculated as the (\[post-BL value minus the BL value\] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available then that single value was used as BL. PCFB in LDL-C was analyzed using ANCOVA, with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 24
percent changeBempedoic AcidPlacebo
Percent Change From Baseline in LDL-C at Week 24-21.17 ± 1.411-2.26 ± 1.552
Statistical analysis
  • Bempedoic Acid vs Placebo · ANCOVA · p = <0.001 · Least squares means difference: -18.91 · 95% CI -22.951 to -14.865BA therapy minus placebo
SecondaryPercent Change From Baseline in the Lipid Profile at Week 12

PCFB was calculated as: (\[post-BL value minus the BL value\] divided by the BL value) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. apoB and TC BL were defined as the last non-missing value on/prior to Day 1. PCFB was analyzed using ANCOVA, with treatment and group stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing data at Week 12 who were no longer taking study treatment (ST), missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking ST, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Lipid Profile at Week 12
percent changeBempedoic AcidPlacebo
non-HDL-C-18.08 ± 1.114-0.14 ± 1.169
TC-15.37 ± 0.879-0.61 ± 0.961
apoB-14.65 ± 1.0800.32 ± 1.177
Statistical analysis
  • Bempedoic Acid vs Placebo · ANCOVA · p = <0.001 · Least squares means difference: -17.94 · 95% CI -21.070 to -14.811BA therapy minus placebo
  • Bempedoic Acid vs Placebo · ANCOVA · p = <0.001 · Least squares means difference: -14.76 · 95% CI -17.283 to -12.239BA therapy minus placebo
  • Bempedoic Acid vs Placebo · ANCOVA · p = <0.001 · Least squares means difference: -14.96 · 95% CI -18.062 to -11.866BA therapy minus placebo
SecondaryPercent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12

Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline for hsCRP is defined as the last non-missing value on or prior to Day 1. Percent change from Baseline in hsCRP, non-parametric (Wilcoxon rank-sum test) analysis with Hodges-Lehmann estimates and confidence interval was performed.

Time frame:
Baseline; Week 12
Reported as:
Median · percent change
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12
percent changeBempedoic AcidPlacebo
Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 12-25.37 (-52.75 to 10.78)2.67 (-31.07 to 38.04)
Statistical analysis
  • Bempedoic Acid vs Placebo · Wilcoxon rank sum test · p = <0.001 · Median treatment difference: -24.290 · 95% CI -35.888 to -12.712BA therapy minus placebo
SecondaryAbsolute Change From Baseline in LDL-C at Week 12 and Week 24

Change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the last two non-missing values on or prior to Day 1.

Time frame:
Baseline; Week 12; Week 24
Reported as:
Mean · mg/dL
Absolute Change From Baseline in LDL-C at Week 12 and Week 24
mg/dLBempedoic AcidPlacebo
Week 12-39.3 ± 33.37-3.1 ± 23.66
Week 24-37.0 ± 35.27-5.1 ± 26.50

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bempedoic Acid0/234 (0%)14/234 (6%)88/234 (37.6%)
Placebo0/111 (0%)4/111 (3.6%)45/111 (40.5%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventBempedoic AcidPlacebo
Angina unstableCardiac disorders3/2340/111
Coronary artery diseaseCardiac disorders3/2340/111
Acute kidney injuryRenal and urinary disorders0/2341/111
Aortic aneurysmCardiac disorders0/2341/111
Escherichia pyelonephritisRenal and urinary disorders0/2341/111
Escherichia sepsisBlood and lymphatic system disorders0/2341/111
NephrolithiasisRenal and urinary disorders0/2341/111
Traumatic intracranial haemorrhageNervous system disorders0/2341/111
Angina pectorisCardiac disorders1/2340/111
Cerebrovascular accidentBlood and lymphatic system disorders1/2340/111
Most frequent other events
Showing 10 of 18
Most frequent other events
EventBempedoic AcidPlacebo
Urinary tract infectionInfections and infestations7/2349/111
MyalgiaMusculoskeletal and connective tissue disorders11/2348/111
FatigueGeneral disorders8/2347/111
ArthralgiaMusculoskeletal and connective tissue disorders14/2345/111
Pain in extremityMusculoskeletal and connective tissue disorders13/2344/111
BronchitisInfections and infestations6/2346/111
NasopharyngitisInfections and infestations3/2345/111
Muscle spasmsMusculoskeletal and connective tissue disorders10/2345/111
HypertensionVascular disorders10/2342/111
Back painMusculoskeletal and connective tissue disorders7/2344/111

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bempedoic AcidPlaceboTotal
Mean65.2 ± 9.6665.1 ± 9.2165.2 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)Bempedoic AcidPlaceboTotal
Female13361194
Male10150151
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bempedoic AcidPlaceboTotal
American Indian or Alaska Native101
Asian628
Native Hawaiian or Other Pacific Islander022
Black or African American161026
White21196307
More than one race011
Unknown or Not Reported000
Baseline LCL-C, Non-HDL-C, TC, HDL-C, and TG Values
Baseline LCL-C, Non-HDL-C, TC, HDL-C, and TG Values(milligrams per deciliter (mg/dL))Bempedoic AcidPlaceboTotal
LDL-C158.48 ± 40.387155.58 ± 38.812157.55 ± 39.854
Non-HDL-C193.49 ± 45.101190.69 ± 43.781192.59 ± 44.637
TC245.66 ± 47.252241.09 ± 44.289244.19 ± 46.304
HDL-C52.17 ± 14.53550.41 ± 14.38451.60 ± 14.489
TG178.96 ± 87.522186.62 ± 96.203181.42 ± 90.336
Baseline Apolipoprotein B (apoB)
Baseline Apolipoprotein B (apoB)(mg/dL)Bempedoic AcidPlaceboTotal
Mean141.0 ± 31.64141.9 ± 30.44141.3 ± 31.22
Baseline High-Sensitivity C-Reactive Protein (hsCRP) Values
Baseline High-Sensitivity C-Reactive Protein (hsCRP) Values(milligrams per liter (mg/L))Bempedoic AcidPlaceboTotal
Median2.920 (1.340 to 5.290)2.780 (1.210 to 5.150)2.900 (1.290 to 5.150)
08

Study locations

67 sites
  • Gilbert, Arizona, United States
  • Anaheim, California, United States
  • Long Beach, California, United States
  • Sacramento, California, United States
  • Santa Ana, California, United States
  • Torrance, California, United States
  • Ventura, California, United States
  • Hamden, Connecticut, United States
  • Daytona Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Site 1
    Miami, Florida, United States
  • Site 2
    Miami, Florida, United States
  • Orlando, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Savannah, Georgia, United States
  • Meridian, Idaho, United States
  • Evanston, Illinois, United States
  • Evansville, Indiana, United States
  • Iowa City, Iowa, United States
  • Waterloo, Iowa, United States
  • Monroe, Louisiana, United States
  • Slidell, Louisiana, United States
  • Tupelo, Mississippi, United States
  • Lincoln, Nebraska, United States
  • Somerset, New Jersey, United States
  • Binghamton, New York, United States
  • Endwell, New York, United States
  • New Windsor, New York, United States
  • Greensboro, North Carolina, United States
  • Morganton, North Carolina, United States
  • Mount Airy, North Carolina, United States
  • Columbus, Ohio, United States
  • Marion, Ohio, United States
  • Maumee, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Beaver, Pennsylvania, United States
  • Langhorne, Pennsylvania, United States
  • Cumberland, Rhode Island, United States
  • Anderson, South Carolina, United States
  • Summerville, South Carolina, United States
  • Jackson, Tennessee, United States
  • Knoxville, Tennessee, United States
  • Memphis, Tennessee, United States
  • Amarillo, Texas, United States
  • Site 1
    Dallas, Texas, United States
  • Site 2
    Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Clinton, Utah, United States
  • Hampton, Virginia, United States
  • Kenosha, Wisconsin, United States
  • Brossard, Canada
  • Chicoutimi, Canada
  • Gatineau, Canada
  • London, Canada
  • Longueuil, Canada
  • Mirabel, Canada
  • Montréal, Canada
  • Newmarket, Canada
  • Oakville, Canada
  • Peterborough, Canada
  • Pointe-Claire, Canada
  • Saint-Jérôme, Canada
  • Sarnia, Canada
  • Toronto, Canada
  • Victoriaville, Canada
09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8. PubMed 21067804 ↗
  • Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010 May;95(5):2015-22. doi: 10.1210/jc.2009-2689. PubMed 20444930 ↗
  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8. doi: 10.1056/NEJMoa042378. PubMed 15635109 ↗
  • Robinson JG, Stone NJ. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015 Aug 14;36(31):2110-2118. doi: 10.1093/eurheartj/ehv182. Epub 2015 May 20. PubMed 25994746 ↗
  • Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid. J Am Heart Assoc. 2022 Aug 2;11(15):e024531. doi: 10.1161/JAHA.121.024531. Epub 2022 Aug 2. PubMed 35916348 ↗
  • Banach M, Duell PB, Gotto AM Jr, Laufs U, Leiter LA, Mancini GBJ, Ray KK, Flaim J, Ye Z, Catapano AL. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia. JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314. PubMed 32609313 ↗
  • Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662. PubMed 30922146 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 16 months.

Results were first posted in Apr 2020, 2 years after primary completion. A results delay was requested in Sep 2018.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2016
First posted
Dec 9, 2016
StartActual
Nov 16, 2016
Primary completionActual
Mar 16, 2018
CompletionActual
Mar 16, 2018
Results delay requested
Sep 21, 2018
Results first posted
Apr 3, 2020
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02988115
Responsible party
Sponsor
First posted
Dec 9, 2016
Start date
Nov 16, 2016
Primary completion
Mar 16, 2018
Completion
Mar 16, 2018
Results posted
Apr 3, 2020
Last update
Apr 3, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion